Results in Dogs Administered 9.2 Gy TBI and DLA-Nonidentical Marrow Grafts From Unrelated Donors With or Without MoAbs Before Transplant
| MoAb* . | No. of Dogs . | P Value3-151 . | ||
|---|---|---|---|---|
| Studied . | Sustained Engraftment No. (%) . | Graft Rejection No. (%) . | ||
| None | 57 | 10 (18) | 47 (82) | |
| 6.4 (irrelevant) | 7 | 1 (14) | 6 (86) | 1.0 |
| S5 (anti-CD44) | 21 | 14 (67) | 7 (33) | <.0001 |
| IM7 (anti-CD44) | 5 | 1 (20) | 4 (80) | 1.0 |
| S3 (anti-CD44) | 12 | 3 (25) | 9 (75) | .69 |
| MoAb* . | No. of Dogs . | P Value3-151 . | ||
|---|---|---|---|---|
| Studied . | Sustained Engraftment No. (%) . | Graft Rejection No. (%) . | ||
| None | 57 | 10 (18) | 47 (82) | |
| 6.4 (irrelevant) | 7 | 1 (14) | 6 (86) | 1.0 |
| S5 (anti-CD44) | 21 | 14 (67) | 7 (33) | <.0001 |
| IM7 (anti-CD44) | 5 | 1 (20) | 4 (80) | 1.0 |
| S3 (anti-CD44) | 12 | 3 (25) | 9 (75) | .69 |
*MoAb was administered 0.2 mg/kg/d × 6 days before TBI.
Fisher's exact test was used to compare experimental results designated “none.”